Avidity Partners Management’s Iovance Biotherapeutics IOVA Stock Holding History

Avidity Partners Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,382,900	Closed	-$13.2M	–	97
2022 Q3	$13.2M	Sell	1,382,900 -9,400	-0.7%	-$108K	0.27%	63
2022 Q2	$15.4M	Sell	1,392,300 -4,650,919	-77%	-$60.9M	0.35%	45
2022 Q1	$101M	Buy	6,043,219 +2,263,219	+60%	+$35M	2.1%	18
2021 Q4	$72.2M	Buy	3,780,000 +2,317,800	+159%	+$51M	1.53%	23
2021 Q3	$36.1M	Buy	+1,462,200	New	+$34.5M	0.8%	40
2020 Q4	–	Sell	-799,000	Closed	-$26.3M	–	110
2020 Q3	$26.3M	Buy	799,000 +60,453	+8%	+$1.85M	1.22%	27
2020 Q2	$20.3M	Buy	+738,547	New	+$24.3M	1.3%	29

Other funds holding IOVA

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Avidity Partners Management's IOVA Position: Q4 2022 in Review

Avidity Partners Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 1,382,900 shares — an estimated $13.2M sold.

Avidity Partners Management first reported a position in IOVA in Q2 2020 and held it in 7 quarters. The position peaked at $101M in Q1 2022. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

Avidity Partners Management reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Avidity Partners Management sold 1,382,900 Iovance Biotherapeutics shares in Q4 2022, an estimated $13.2M.
Avidity Partners Management first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 7 quarters.
Avidity Partners Management's Iovance Biotherapeutics position peaked at $101M in Q1 2022.
218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.